Compositions and methods for treating cognitive impairment in patients with Down syndrome

摘要

This application relates to compounds having inverse agonist functional selectivity for GABA A receptors containing the ±5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The present application also relates to the use of compounds having inverse agonist functional selectivity for GABA A receptors containing the ±5 subunit for the preparation of a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The application further relates to pharmaceutical compositions for treating cognitive impairments in subjects suffering from Down syndrome comprising a compounds having inverse agonist functional selectivity for GABA A receptors containing the ±5 subunit, or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). The present application also describes methods for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more compounds having inverse agonist functional selectivity for GABA A receptors containing the ±5 subunit. More particularly, the present application is concerned with the treatment of cognitive impairments, such as impairment in memory, learning capacity or both, in subjects suffering from Down syndrome.